Recovery Peptides Anti-aging Neuropeptides Under research

DSIP

Also known as: Delta Sleep-Inducing Peptide

DSIP (Delta Sleep-Inducing Peptide) is an endogenous neuropeptide, discovered in 1974, which, as its name suggests, was initially linked with promoting deep slow-wave (delta phase) sleep. Despite its name, it has been discovered to be a systemic adaptogenic neuromodulator that greatly reduces the body's reactivity to stress, balancing hormonal levels and reducing pain and withdrawal.

Mechanism of action

Acts as an adaptogen, interacting with the hypothalamic-pituitary-adrenal (HPA) axis.
Modulates neurological excitability reducing glutamate overactivity.
Decreases stress-induced excessive Cortisol release.
Promotes electroencephalographic brainwave profiles facilitating deep restorative sleep, though it does not "force" sleep like a sedative.

Uses & indications

Insomnia and sleep: Dramatically improves the quality of REM and slow-wave sleep without "hangover" sedative effects.
Stress management: Adaptogenic intervention to mitigate chronic fatigue and oxidative stress from high cortisol levels.
Withdrawal syndrome: Used experimentally with high success to treat alcohol or opiate withdrawal syndromes.

Effects

Greater ease in falling asleep, profound feeling of rest, feeling of systemic calm, and reduction of morning anxiety.

Considerations & contraindications

Its effect to induce sleep in people without deficiencies is not guaranteed; it works best stabilizing broken circadian rhythms.
Can be injected 1 to 3 hours before bed to get better sleep architecture results.

Regulatory approval

Approved and medically used in parts of Eastern Europe. Not FDA approved.

Dosage

Normally doses ranging from 100mcg to 300mcg are used, administered 1 to 3 hours before bed.

Storage

Lyophilized at -20°C. Reconstituted at 4°C, use within weeks.

Technical data

Regulatory status Under research

Molecular weight 848.9 Da

Half-life Aproximadamente 10 a 15 minutos en plasma

Administration routes Subcutánea